VR Logo

Cardiff Oncology Inc. (CRDF) download report


Healthcare | Biotechnology & Pharma Research

Cardiff Oncology Inc. (CRDF) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.

IPO Date: 27-Jul-2004

CEO & Director: Dr. Mark Erlander Ph.D.

Chief Financial Officer: Mr. James E. Levine

Listing: NASDAQ: CRDF

Country: United States

Headquarters: San Diego, CA

Website: https://www.cardiffoncology.com

Key Facts

Market cap: $96.14 Mln

Revenue (TTM): $0.36 Mln

Earnings (TTM): $-34.13 Mln

Cash: $129.36 Mln

Total Debt: $3.10 Mln

Insider's Holding: 7.12%

Liquidity: Low

52 Week range: $1.13 - 8.58

Shares outstanding: 43,306,100

10 Years Aggregate:

  • CFO: $-167.24 Mln
  • EBITDA: $-194.06 Mln
  • Net Profit: $-209.76 Mln

Stock Performance

Time Period Cardiff Oncology (CRDF) S&P BSE Sensex S&P Small-Cap 600
YTD-63.98-8.97-19.67
1 month66.54-3.38-9.84
3 months-12.35-7.93-15.05
1 Year-72.490.55-18.10
3 Years-4.6810.415.71
5 Years-52.1611.455.53
10 Years-38.3012.0510.04
As on 29-Jun-2022
Year Cardiff Oncology (CRDF) S&P Small-Cap 600 S&P BSE Sensex
2021-66.5925.2721.99
20201,350.819.5715.75
2019-60.6720.8614.38
2018-85.61-9.705.87
2017-85.3611.7327.91
2016-61.1124.741.95
201525.58-3.36-5.03